On Friday, DiamondRock Hospitality Company (NYSE:DRH)’s shares declined -1.66% to $11.26.
DiamondRock Hospitality Company (DRH), a lodging-focused real estate investment trust that owns a portfolio of 29 premium hotels in the United States, recently declared results of operations for the quarter ended June 30, 2015.
Second Quarter 2015 Highlights
- Pro Forma RevPAR: Pro Forma RevPAR was $184.50, an enhance of 6.0% from the comparable period of 2014 and a new record for the Company.
- Pro Forma Hotel Adjusted EBITDA Margin: Pro Forma Hotel Adjusted EBITDA margin was 34.56%, an enhance of 166 basis points from 2014.
- Pro Forma Hotel Adjusted EBITDA: Pro Forma Hotel Adjusted EBITDA was $85.4 million, an enhance of 11.3% from 2014.
- Adjusted EBITDA: Adjusted EBITDA was $81.1 million, an enhance of 14.3% from 2014.
- Adjusted FFO: Adjusted FFO was $61.5 million and Adjusted FFO per diluted share was $0.31.
- Key West Acquisition: The Company attained the 184-suite Sheraton Suites Key West for $94.0 million on June 30, 2015.
DiamondRock Hospitality Company, a lodging focused real estate company, owns premium hotels and resorts in North America. The company operates its hotels under the Hilton, Marriott, and Westin brand names in New York, Los Angeles, Chicago, Boston, and Atlanta; and in destination resort locations, such as the United States Virgin Islands and Colorado.
ARM Holdings plc (ADR) (NASDAQ:ARMH)’s shares dropped -0.95% to $42.58.
ARM Holdings plc (ADR) (ARMH) has signed an expansive long-term graphics technology agreement with Samsung to enable the creation of next generation devices capable of delivering even more compelling visual experiences. The subscription license covers ARM® Mali™ graphics processing units (GPUs) counting the Mali-T820/830/860, the recently declared Mali-T880 and all future Mali GPUs.
This long term contract with ARM allows Samsung to continue creating innovative products addressing a range of price and performance points to meet the evolving needs of multiple markets. Samsung is already utilizing ARM Mali technology in SoCs powering an impressive range of leading consumer products.
ARM Holdings plc, together with its auxiliaries, designs microprocessors, physical intellectual property (IP), and related technology and software. The company also sells development tools that enhance the performance of embedded applications. Its products comprise microprocessor cores that comprise of specific functions, such as video, graphics, and display technology IP; and physical IP components for the design and manufacture of integrated circuits, which comprise embedded memory, standard cell, and input/output components.
At the end of Friday’s trade, Endo International plc - Ordinary Shares (NASDAQ:ENDP)‘s shares dipped -1.96% to $73.00.
Endo International plc (ENDP) declared that the U.S. District Court for the Southern District of New York has issued a ruling upholding two Endo patents covering OPANA® ER, the Company’s opioid agonist indicated for the administration of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The ruling also determined that Endo’s patents had been infringed by all of the defendants. As a result, it is predictable that the generic version of non-crush-resistant OPANA® ER presently sold by Actavis, the U.S. generics business of Allergan, Inc., will be removed from the market and additional approved but not yet marketed generic versions of the product developed by other generic companies will not be launched in the near term.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, counting Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology.
Ameren Corp (NYSE:AEE), ended its Friday’s trading session with -1.76% loss, and closed at $38.56.
Ameren Corporation (AEE) declared second quarter 2015 net income in accordance with generally accepted accounting principles (GAAP) of $150 million, or 61 cents per share, contrast to second quarter 2014 GAAP net income of $149 million, or 61 cents per share. Not taking into account results from suspended operations and a 2015 loss provision for disongoing pursuit of a construction and operating license (COL) for a second nuclear unit at Ameren Missouri’s Callaway Energy Center, Ameren recorded second quarter 2015 core (non-GAAP) net income of $141 million, or 58 cents per share, contrast with second quarter 2014 core net income of $150 million, or 62 cents per share.
The year-over-year decrease in second quarter 2015 core earnings reflected lower retail electric sales volumes driven primarily by milder early summer temperatures in 2015. In addition, the earnings comparison was negatively affected by a seasonal rate redesign and the timing of revenues under formula ratemaking related to Ameren Illinois electric delivery, in addition to higher depreciation and amortization expenses. The effects of these factors were partially offset by earnings on raised investments in electric transmission and delivery infrastructure made under formula ratemaking and a lower effective income tax rate.
Ameren Corporation operates as a public utility holding company in the United States. The company engages in the rate-regulated electric generation, transmission, and distribution; and rate-regulated natural gas transmission and distribution businesses.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
